ARP Rheumatology

Introduction Systemic sclerosis (SSc) is a connective tissue disease with multi-system involvement and it has an increased risk of developing hematologic malignancies. This study aims to report the association between hematologic malignancies with SSc and to characterize in-hospital demographics and outcomes in patients with hematologic malignancies with and without SSc. Methods We performed a retrospective review of pooled data from the National Inpatient Sample (NIS) database from 2016 to 2020. Crude prevalence of hematologic malignancies among hospitalized patients with and without SSc was calculated. Logistic regression was used for statistical significance of differences in prevalence while adjusting for confounders. Demographic characteristics and outcomes of patients with hematologic malignancies with and without SSc was compared. Statistical analysis was done using chi-square and multivariate logistic regression. Results Among all adult hospitalizations, the prevalence of hematologic malignancy was 1.87% compared to 2.66% among patients with SSc (adjusted odds ratio (aOR) 1.52, p <0.01). Relative to the non-SSc group, the SSc group had higher odds of in-patient mortality (OR 1.43; 95% confidence interval (CI) 1.11 - 1.87; p<0.01). The prevalence of lymphoma was 0.71% compared to 1.04% among patients with SSc (aOR 1.6, p < 0.01). Relative to the non-SSc group, the lymphoma-SSc group had similar odds of in-patient mortality (OR 0.93; 95% CI 0.55 - 1.59; p=0.80). The prevalence of leukemia was 0.79% compared to 1.28% among patients with SSc (aOR 1.74, p < 0.01). The leukemia-SSc group had higher odds of in-patient mortality (OR 1.78; 95% CI 1.29 - 2.46; p<0.01). For myeloma, there was no difference in the prevalence in adults with and without SSc (0.4 vs. 0.38%, aOR 0.96, p=0.64) and there was no difference of in-hospital mortality. Conclusions There is a positive significant association between hematologic malignancies including lymphoma and leukemia, and SSc. This association was not seen between myeloma and SSc. There is increased in-hospital mortality of patients with leukemia and SSc.

Maria Emilia Romero Noboa

Rafaella Litvin

Faria Sami

Saman Tanveer

Nationwide analysis of adult hospitalizations with hematologic malignancies and systemic sclerosis

全国成人血液系统恶性肿瘤与系统性硬化症住院患者的分析

This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (휏=0.570, p.

Maria Seabra Rato

Filipe Oliveira Pinheiro

Salomé Garcia

Bruno Fernandes

Alexandra Bernardo

Rita Gaio

Lúcia Costa

Miguel Bernardes

FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density – are we treating our patients under bDMARDs?

类风湿性关节炎患者使用和不使用骨密度评估的FRAX 10年骨折风险——我们是否在使用生物制剂DMARDs时治疗不足？

To characterize patients evaluated in our Early Arthritis Clinic (EAC) in the first ten years; to assess diagnostic delay and its underlying causes; and to evaluate the level of agreement between the referring physician and the rheumatologist regarding the presence of referral criteria.

A Maduro

A Pinto Saraiva

B Mendes

A Carones

M Luis

T Santiago

JA Pereira da Silva

C Duarte

10-year experience of early arthritis clinic at a tertiary rheumatology center: achievements and challenges

三级风湿病中心早期关节炎门诊的10年经验：成就与挑战

Filipa Farinha

Anisur Rahman

ARP Rheumatol

Lupus nephritis outcomes – is the picture changing?

狼疮性肾炎的预后——现状是否在改变？

Agnieszka Foryś

Jakub Wroński

Mateusz Płaza

Małgorzata Wisłowska

Intestinal (pseudo-)obstruction and hydronephrosis – consider lupus

肠（假）梗阻与肾积水——考虑狼疮

Margarida Santos Faria

Iolanda Godinho

Estela Nogueira

Joana Tavares

Daniel Carvalho

Cristina Ponte

Rheumatoid arthritis and ANCA-associated vasculitis - an unusual overlap successfully treated with rituximab

类风湿性关节炎与抗中性粒细胞胞浆抗体相关性血管炎——一种成功使用利妥昔单抗治疗的罕见重叠综合征

Introduction: It is important to assess the risk of vertebral fractures (VFs) in patients with rheumatoid arthritis (RA), as RA is associated with a high risk of VFs. However, the epidemiology and risk of VFs in patients with RA remain inconclusive. The present study therefore clarified the prevalence and associated factors of VFs in patients with RA. Methods: We included 107 patients (19 men and 88 women) and retrospectively investigated the number and location of VFs, bone mineral density (BMD), RA disease activity score for 28 joints based on C-reactive protein (DAS28-CRP), and history of medication for RA and osteoporosis. Based on the investigated items, we assessed the prevalence of VFs in patients with RA and the association between the clinical parameters of RA patients and VFs. Results: The average age, disease duration, and DAS28-CRP were 67.9 years old, 14.9 years, and 2.2, respectively. We found that the prevalence of VFs in patients with RA was 30.8%, and 84.8% of patients with VFs and 62.2% of those without VFs had been treated for osteoporosis. We further found that the prevalence of VFs in patients with RA with a history of anti-osteoporotic agent use was 37.8%. In univariate analyses, patients with RA with VFs had significantly higher DAS28-CRP values, a higher rate of corticosteroid use, and lower BMD (p = 0.018, p = 0.004, and p &lt; 0.001, respectively) than those without VFs. A multivariable logistic regression analysis and ordinal logistic analysis revealed that the DAS28-CRP and BMD were independent factors associated with the presence (p = 0.042 and p = 0.011, respectively) and number (p = 0.036 and p = 0.048, respectively) of VFs. Conclusions: The prevalence of VFs was relatively high in patients with RA, regardless of the use of anti-osteoporotic agents. A high disease activity score and low BMD are associated with the presence and number of VFs in patients with RA. Based on these findings, to reduce VFs in RA patients, it is important to tightly control the disease activity of RA in addition to osteoporosis treatment.

H Sakane

K Okamura

Y Iizuka

A Honda

E Takasawa

T Mieda

Y Yonemoto

T Suto

T Kaneko

H Chikuda

High disease activity influences the presence of vertebral fractures in rheumatoid arthritis

高疾病活动度影响类风湿性关节炎患者椎体骨折的发生

Ana Catarina Moniz

Marta Teixeira Almeida

Bruno Pereira

Ana Valido

Gastrointestinal bleeding – an atypical presentation of granulomatosis with polyangiitis

胃肠道出血——肉芽肿性多血管炎的非典型表现

We aimed to identify clinical and serological predictors of myositis in mixed connective tissue disease (MCTD).

Ana Teresa Melo

Manuel Silvério-António

Joana Martins-Martinho

Francisca Guimarães

Eduardo Dourado

Daniela Oliveira

Jorge Lopes

André Saraiva

Ana Gago

Margarida Correia

Ana Lúcia Fernandes

Sara Dinis

Rafaela Teixeira

Susana Pinto Silva

Carlos Costa

Tiago Beirão

Carolina Furtado

Pedro Abreu

Nikita Khmelinskii

Predictors of myositis in mixed connective tissue disease: a multicentre retrospective study

混合性结缔组织病中肌炎预测因素的多中心回顾性研究

Classification criteria for large vessel vasculitis

大血管血管炎的分类标准

Abbreviation
Journal Impact	1.59
Quartiles(Global)	RHEUMATOLOGY(Q3)

Publication Information	Publisher: Sociedade Portuguesa de Reumatologia，Publishing cycle: ，Journal Type: journal，Open Access Journals: No
Basic data	Year of publication: 2022，Proportion of original research papers: 70.37%，Self Citation Rate:， Gold OA Rate: 0.00%

ARP Rheumatology

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience